Bjerrum P, Illum P
Allergy. 1985 Jan;40(1):65-9. doi: 10.1111/j.1398-9995.1985.tb04156.x.
The aim of this study was to compare the efficacy and side effects of budesonide and disodium cromoglycate (DSCG) in seasonal allergic rhinitis. In a double-blind, double-dummy comparative study, 43 patients with seasonal allergic rhinitis were either treated with budesonide (200 micrograms b.d.) or DSCG (5.2 mg 5 times daily). After a 1 week run-in period treatment was given for 3 weeks. The patient scorings for nasal secretion, nasal itching, sneezing bouts and total nasal symptoms were significantly different between the treatment groups during the whole treatment period. The scorings for nasal blockage were significantly different during the last 2 weeks of treatment. All differences were in favour of budesonide treatment. The patients' assessment of the treatment favoured budesonide (P less than 0.02). Side effects were few and mild, but one patient from the budesonide group stopped treatment because of headache.
本研究旨在比较布地奈德与色甘酸钠（DSCG）治疗季节性变应性鼻炎的疗效和副作用。在一项双盲、双模拟对照研究中，43例季节性变应性鼻炎患者分别接受布地奈德（每日2次，每次200微克）或色甘酸钠（每日5次，每次5.2毫克）治疗。经过1周的导入期后，进行3周的治疗。在整个治疗期间，各治疗组患者在鼻分泌物、鼻痒、喷嚏发作及总的鼻部症状评分方面存在显著差异。在治疗的最后2周，鼻塞评分存在显著差异。所有差异均表明布地奈德治疗更具优势。患者对治疗的评估也更倾向于布地奈德（P<0.02）。副作用少且轻微，但布地奈德组有1例患者因头痛而停止治疗。
